Please Download Flash

Browse News by Year:
RSS  RSS

 

Michael J. Fox Foundation Awards Research Grant to EnVivo as Part of Initiative Seeking New Parkinson's Disease Treatments
Send To a Colleague Send To a Colleague Send To a Colleague
Send To a Colleague
Print Printable Version
Email To a Colleague Send to a Colleague
Send To a Colleague
Send To a Colleague Send To a Colleague Send To a Colleague

Watertown, MA, January 19, 2010 - EnVivo Pharmaceuticals, Inc. has been awarded a research grant by the Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grant will fund research as part of the foundation’s Therapeutics Development Initiative that seeks new treatments for Parkinson’s disease.

Under this 19-month grant, EnVivo will test its Histone Deacetylase inhibitor (HDACi) EVP-0334 in two different mouse models of Parkinson’s disease to demonstrate that EVP-0334 can potentially slow the progression of Parkinson’s disease. EVP-0334 is currently being clinically developed by EnVivo for the treatment of Alzheimer’s disease.

HDACs are a family of enzymes that epigenetically regulate gene expression and can affect protein clearance. Inhibitors of HDACs have previously been reported to be efficacious in cellular and animal models of Parkinson’s disease.